RxDoctor Payments Data

Tara Hamilton, MD

Endocrinology, Diabetes & Metabolism · Medford, MANPI 1326181710

Payments from drug & device makers

$66in general payments, 2019–2025

Across 2 payments — averaging $33.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$50
  • Novo Nordisk$16

What the payments were for

  • Food & beverage$66100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen1$50
Novo Nordisk1$16

How this compares

$66 in reported general payments places this provider in the 10th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts

Medicare billing

Part B allowed, 2024
$371,354
Medicare patients
445
Services billed
17,678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide234$434,777
MounjaroTirzepatide127$266,137
TrulicityDulaglutide121$233,998
JardianceEmpagliflozin127$186,689
JanuviaSitagliptin Phosphate69$81,626
Teriparatide27$74,824
ForteoTeriparatide12$49,753
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog72$33,480
Tresiba Flextouch U-200Insulin Degludec17$24,471
Humalog Kwikpen U-100Insulin Lispro49$19,905
Tresiba Flextouch U-100Insulin Degludec25$15,741
Lantus SolostarInsulin Glargine,hum.Rec.Anlog88$14,570
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/716$13,303
Novolog FlexpenInsulin Aspart26$6,927
Nano 2nd Gen Pen NeedlePen Needle, Diabetic69$6,116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$16$438,134254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

Other endocrinology, diabetes & metabolism in Medford

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →